established a dual‐targeting theranostic nanoplatform (UCNP@Tf‐RB) that combines transferrin‐mediated active targeting with UCNP for MRI/PTI‐guided synergistic PTT/PDT therapy.[294] This method realized superior tumor suppression, with a tumor‐growth inhibition index (TGII) of ≈0.91, through a FRET‐mediated mechanism with minimal systemic toxicity. This evidence concerns the gene RB1 and neoplasm.